Kidney transplantation in HIV-infected patients

Seminars in Dialysis

Volumn 18, Issue 6, 2005, Pages 495-498

  Wyatt, Christina M ^a   Murphy, Barbara ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 30744468562     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2005.00095.x     Document Type: Review

References (40)

1. UNAIDS: AIDS Epidemic Update 2003. Geneva: UNAIDS, 2003
2. Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report. Atlanta: Centers for Disease Control and Prevention. 2004
3. Selik RM, Byers RH Jr, Dworkin MS: Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 29:378-387, 2002
4. Schwartz EJ, Szczech LA, Ross MJ, Klotman ME, Winston JA, Klotman PE: Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 16:2412-2420, 2005
5. U.S. Renal Data System: USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004
6. Ahuja TS, Grady J, Khan S: Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. Am J Kidney Dis 13:1889-1893, 2002
7. Spital A: Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of U.S. transplant centers. Transplantation 65:1187-1191, 1998
8. Karpas A, Lowdell M, Jacobson SK, Hill F: Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK506. Proc Natl Acad Sci USA 89:8351-8355, 1992
9. Billich A, Hammerschmid F, Peichl P, Wenger R, Zenke G, Quesniaux V, Rosenwirth B: Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HJV prorein-cyclophilin A interactions. J Virol 69:2451-2461, 1995
10. Franke EK, Luban J: Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology 222:279-282, 1996
11. Margolis D, Heredia A, Gaywee J, Drusano G, Oldach D, Redfield RR: Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 21:362-370, 1999
12. Hossain MM, Coull JJ, Drusano GL, Margolis DM: Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antivir Res 55:41-52, 2002
13. Roy J, Paquette JS, Fortin JF, Tremblay MJ: The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 46:3447-3455, 2002
14. Heredia A, Amoroso A, Davis C, Le N, Reardon E, Dominique JK, Klingebiel E, Gallo RC, Redfield RR: Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci USA 100:10411-10416, 2003
15. Rizzardi GP, Harari A, Capiluppi B, Tambussi G, Ellefsen K, Ciuffreda D, Champagne P, Bart PA, Chave JP, Lazzarin A, Pantaleo G: Treatment of primary HIV-1 infection with cyclosporín A coupled with highly active antiretroviral therapy. J Clin Invest 109:681-688, 2002
16. Dummer JS, Erb S, Breinig MK, Ho M, Rinaldo CR Jr, Gupta P, Ragni MV, Tzakis A, Makowka L, Van Thiel D, et al.: Infection with human immunodeficiency virus in the Pittsburgh transplant population. A study of 583 donors and 1043 recipients, 1981-1986. Transplantation 47:134-140, 1989
17. Schwarz A, Offermann G, Keller F, Bennhold I, L'Age-Stehr J, Krause PH, Mihatsch MJ: The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation - data on four cases and review of the literature. Transplantation 55:95-103, 1993
18. Tzakis AG, Cooper MH, Dummer JS, Ragni M, Ward JW, Starzl TE: Transplantation in HIV+ patients. Transplantation 49:354-358, 1990
19. Abbott KC, Swanson SJ, Agodoa LY, Kimmel PL: Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 15:1633-1639, 2004
20. Ragni MV, Belle SH, Im K, Neff G, Roland M, Stock P, Heaton N, Humar A, Fung JF: Survival of HIV-infected liver transplant recipients. J Infect Dis 188:1412-1420, 2003
21. Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, Terrault NA, Frassetto LA, Palefsky JM, Tomlanovich SJ, Ascher NL: Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 76:370-375, 2003
22. Kumar MSA. Sierka DR, Damask AM, Fyfe B, McAlack RF, Heifets M, Moritz MJ, Alvarez D, Kumar A: Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 67:1622-1629, 2005
23. Schonder KS, Shullo MA, Okusanya O: Tacrolimus and lopinavir/ritonavir interaction in liver transplantation. Ann Pharmacother 37:1793-1796, 2003
24. Jain AK, Venkataramanan R, Shapiro R, Scantlebury VP, Potdar S, Bonham CA, Ragni M, Fung JJ: The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl 8:841-845, 2002
25. Jain AB, Venkataramanan R, Eghtesad B, Marcos A, Ragni M, Shapiro R, Rafail AB, Fung JJ: Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl 9:954-960, 2003
26. Press N, Tyndall MW, Wood E, Hogg RS, Montaner JSG: Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 31(suppl 3):S112-S117, 2002
27. Lok AS, McMahon BJ: Chronic Hepatitis B, Alexandria, VA: American Association for the Study of Liver Diseases, 2004
28. Tan AC, Brouwer JT, Glue P, van Leusen R, Kauffmann RH, Schalm SW, de Vries RA, Vroom B: Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 16:193-195, 2001
29. Degos F, Pol S, Chaix ML, Laffitte V, Buffet C, Bernard PH, Degott C, Carnot F, Riffaud PC, Chevret S: The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 16:1017-1023, 2001
30. Casanovas-Taltavull T, Baliellas C, Benasco C, Serrano TT, Casanova A, Perez JL, Guerrero L, Gonzalez MT, Andres E, Gil-Vernet S, Casais LA: Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 96:1170-1177, 2001
31. Gursoy M, Gur G, Arslan H, Ozdemir N, Boyacioglu S: Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat 8:70-77, 2001
32. Strader DB, Wright T, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147-1171, 2004
33. Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh J, Thio C, Benhamou Y: Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 19:221-240, 2005
34. Bani-Sadr F, Palmer P, Scieux C, Molina JM: Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. Clin Infect Dis 39:1062-1064, 2004
35. Lacombe K, Gozlan J, Boelle PY, Serfaty L, Zoulim F, Valleron AJ, Giraud PM: Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. AIDS 19:907-915, 2005
36. Schildgen O, Schewe CK, Vogel M, Daumer M, Kaiser R, Weitner L, Matz B, Rockstroh JK: Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. AIDS 18:2325-2327, 2004
37. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT, APRICOT Study Group: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351:438-450, 2004
38. Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P, Italian Co-Infection Study (ICOS) Group: Open, randomized, multicentre Italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antiviral Ther 10:309-317, 2005
39. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, Reiss P, Thiebaut R, Weiland O, Yazdanpanah Y, Zeuzem S, ECC Jury: Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 42:615-624, 2005
40. Solid Organ Transplantation in HIV: multi-site study. Available at http://www.clinicaltrials.gov/ct/show